Ginwa Enterprise (Group) Inc.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Jinhua Enterprise (Group) Co., Ltd. is a listed company in the field of pharmaceutical logistics, led by the R&D, production and marketing of traditional Chinese patent medicines and simple preparations, biological medicine and chemical medicine. It was listed on the Shanghai Stock Exchange on June 12, 1997, with the stock code of 600080, referred to as Jinhua Shares. After 20 years of rapid development, Jinhua Group has now formed a complete system for drug research and development, production, and sales. The subsidiary of the company, Xi'an Jinhua Pharmaceutical Factory, is located at 202 Keji Fourth Road, Xi'an High tech Industrial Development Zone. It has more than ten advanced production lines, including extraction workshop, solution, tablet, capsule, granule, and Jintiange capsule dedicated workshop. It is currently the exclusive industrial production base for artificial tiger bones worldwide. The company's leading product, Artificial Tiger Bone Powder/Jintiange Capsule, is a national first-class new drug approved by CFDA, with patented technology and independent intellectual property rights. In 2003, it was awarded the "National High tech Industrialization Demonstration Project (Modern Chinese Medicine Special Project)"; As a substitute for natural tiger bone, Jintiange Capsule has grown into a leader of traditional Chinese patent medicines and simple preparations in the treatment of osteoporosis. It has driven the development of products with advanced technology and has always been in the forefront of clinical orthopedic traditional Chinese patent medicines and simple preparations. The "Jinhua" brand transfer factor series drugs, as human immune regulatory drugs, have consistently ranked among the top in the national market due to their high quality and safety; The "Jinhua" brand children's series of drugs has formed a competitive advantage of stable quality, excellent price, and safety and reliability through years of continuous operation, and has been recognized and welcomed by a large number of patients. Adhering to the corporate mission of "Healthy People, Golden Flower Responsibility", the company attaches great importance to the construction of product quality and safety systems, strictly implements national GMP management standards throughout the entire operation process, and has won widespread praise by providing high-quality drugs with precise therapeutic effects and safe and reliable safety for the people. Facing the future, guided by the development vision of "committed to the modernization of China's pharmaceutical industry, becoming a leader in the skeletal muscle field and a leader in modern Chinese medicine", Jinhua Group is fully striving to become one of China's top pharmaceutical enterprises. |
| Headquarter | Xi'an |
| Establish Date | 2/14/1996 |
| Listed Code | 600080.SH |
| Listed Date | 6/12/1997 |
| Chairman | Xing Yajiang. |
| CEO | Han Zhuojun. |
| Website | www.ginwa.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
